Responses
Paper
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study
Compose a Response to This Article
Other responses
No responses have been published for this article.